Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity

• Principais autores: Mohammad Hossein Ataee (Autor), Seyed Ali Mirhosseini (Autor), Reza Mirnejad (Autor), Ehsan Rezaie (Autor), Hamideh Mahmoodzadeh Hosseini (Autor), Jafar Amani (Autor)
• Formato: Livro
• Publicado em: Wolters Kluwer Medknow Publications, 2022-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background and purpose: The lack of a new effective treatment for small cell lung cancer (SCLC) is an unresolved problem. Due to the new identification of delta-like ligand 3 (DLL3) and its high expression in SCLC patients, the use of DLL3 in target therapy can be effective. The use of bacterial tox...